Charles Sailey, M.D., M.S., FCAP

Charles Sailey, MD, MS, FCAP | Laboratory Director

Dr. Charles Sailey obtained dual master degrees in cell biology and biotechnology before medical training. After obtaining his medical degree from Ross University School of Medicine, he completed residency training in Anatomic & Clinical Pathology at the University of Maryland, followed by fellowship training in Molecular Genetic Pathology at the University of North Carolina. As medical and scientific director of the Molecular Genetic Pathology, Molecular Microbiology, Metabolic Genetics, and Clinical Chemistry laboratories at Arkansas Children’s Hospital, he planned, designed, and coordinated the construction of a human genetics laboratory in 2011. Since that time, the laboratory has thrived and is now offering a full genetic test menu, including targeted mutation analysis using Sanger sequencing, MLPA, and copy-number variation using a SNP microarray, among others. He had several ongoing internal research projects, including the construction of a 15 target plasmid for limit-of-detection and QA studies (patent pending) used with various PCR assays. Other projects included downstream analysis of archived DNA correlated with degree of apoptotic laddering, correlation studies between homebrew and commercial platforms for various molecular assays (including C. diff, sepsis, respiratory infections, PCR, and DNA sequencing), and genotyping various strains of infectious organisms in Arkansas. He also spearheaded an extensive review of all send-out genetic tests for appropriateness and cost effectiveness at a large pediatric hospital. He currently has two larger studies still underway; one involves characterizing miRNA biomarkers in children who have had LVAD placement to help stratify individuals with reverse remodeling from those advancing to end-stage heart failure. The other involves creating a custom next-generation sequencing panel looking at genes involved in psychiatric drug metabolism for nonresponsive patients. Recently, he developed the next generation sequencing core facility at Arkansas Children’s Hospital, with custom designed novel autism and hereditary disease gene panels. Dr. Sailey has over 40 peer reviewed publications, book chapters, and presentations, including data presented at national conferences.


Mariko Nakano PhD | Senior Scientist

Dr. Mariko Nakano joined the Molecular Testing Labs after completing a post-doctoral fellowship at the U.S. Food and Drug Administration, where she studied the highly polymorphic drug-metabolizing enzyme CYP2D6. Her research focus was to determine and predict CYP2D6-mediated drug-drug interactions for various genotypes. Before the FDA fellowship, she investigated the molecular mechanism of CYP3A4 inactivation by bioactivated ritonavir as a post-doctoral fellow under Dr. Kent Kunze in the University of Washington Medicinal Chemistry Department. She received her Ph.D. in Medicinal Chemistry from the University of Washington under the supervision of Dr. Allan Rettie in 2011. Her graduate work included characterizing the role of a previously orphan cytochrome P450 enzyme – CYP4V2 – in saturated and unsaturated fatty acid homeostasis. Dr. Nakano has published her work in multiple peer-reviewed journals and presented her research at national and international conferences.

Kelly Fobes Pharm D

Kelly T. Fobes, PharmD | Clinical Scientist

Kelly Fobes graduated with honors from Pennsylvania State University where she studied Biochemistry and Molecular Biology. She received her Doctor of Pharmacy degree from Samford University in Birmingham, AL. Her eclectic background includes experience in the pharmaceutical industry, clinical research, fitness training and pharmacy practice. When not at MTL, Kelly enjoys snowboarding, downhill mountain biking and competing in CrossFit. She is passionate about helping people reach their individual goals while living happier and healthier lives.

“Personalized medicine will be the standard of care in the near future, and I am so excited to be on the leading edge of this transformation with an industry-leading company!”